Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):241–243. doi: 10.1128/aac.40.1.241

Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis.

T Ishii 1, M Hosoya 1, S Mori 1, S Shigeta 1, H Suzuki 1
PMCID: PMC163092  PMID: 8787915

Abstract

The ribavirin concentration in hamster brains was measured by a high-performance liquid chromatography (HPLC) system and a bioassay system. When ribavirin was administered intracranially at a dosage of 10 mg/kg of body weight per day for 10 days, a dosage which results in 100% survival of hamsters infected with subacute sclerosing panencephalitis (SSPE) virus and which inhibits the replication of SSPE virus in hamster brains, the ribavirin concentration in the brains estimated by HPLC and bioassay was kept higher than 50 micrograms/g for 10 days. The effective concentration in vivo corresponds to the concentration at which ribavirin completely inhibits the replication of SSPE virus in vitro. The maximal tolerable ribavirin concentration for hamsters was calculated to be 150 micrograms/g. Although ribavirin shows toxicity to the animals at a relatively low concentration (250 to 400 micrograms/g), intrathecal or intraventricular administration of ribavirin should be explored for potential use in the treatment of patients with SSPE, while the ribavirin concentration in cerebrospinal fluid or brain tissue should be monitored.

Full Text

The Full Text of this article is available as a PDF (165.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crumpacker C., Bubley G., Lucey D., Hussey S., Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 5;2(8497):45–46. doi: 10.1016/s0140-6736(86)92590-0. [DOI] [PubMed] [Google Scholar]
  2. De Clercq E., Cools M., Balzarini J., Snoeck R., Andrei G., Hosoya M., Shigeta S., Ueda T., Minakawa N., Matsuda A. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds. Antimicrob Agents Chemother. 1991 Apr;35(4):679–684. doi: 10.1128/aac.35.4.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fukuyama Y., Nihei K., Matsumoto S., Ebina T., Kamoshita S., Sato T., Arima M., Yabuuchi H., Ueda S., Ohtahara S. Clinical effects of MND-19 (Inosiplex) on subacute sclerosing panencephalitis--a multi-institutional collaborative study--The Inosiplex-SSPE Research Committee. Brain Dev. 1987;9(3):270–282. doi: 10.1016/s0387-7604(87)80044-x. [DOI] [PubMed] [Google Scholar]
  4. Gilbert B. E., Wyde P. R., Wilson S. Z., Robins R. K. Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Antimicrob Agents Chemother. 1991 Jul;35(7):1448–1453. doi: 10.1128/aac.35.7.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Honda Y., Hosoya M., Ishii T., Shigeta S., Suzuki H. Effect of ribavirin on subacute sclerosing panencephalitis virus infections in hamsters. Antimicrob Agents Chemother. 1994 Apr;38(4):653–655. doi: 10.1128/aac.38.4.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hosoya M., Shigeta S., Ishii T., Suzuki H., De Clercq E. Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo. J Infect Dis. 1993 Sep;168(3):641–646. doi: 10.1093/infdis/168.3.641. [DOI] [PubMed] [Google Scholar]
  7. Hosoya M., Shigeta S., Nakamura K., De Clercq E. Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in vitro. Antiviral Res. 1989 Sep;12(2):87–97. doi: 10.1016/0166-3542(89)90072-7. [DOI] [PubMed] [Google Scholar]
  8. Jabbour J. T., Garcia J. H., Lemmi H., Ragland J., Duenas D. A., Sever J. L. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA. 1969 Mar 24;207(12):2248–2254. doi: 10.1001/jama.207.12.2248. [DOI] [PubMed] [Google Scholar]
  9. Jones C. E., Dyken P. R., Huttenlocher P. R., Jabbour J. T., Maxwell K. W. Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients. Lancet. 1982 May 8;1(8280):1034–1037. doi: 10.1016/s0140-6736(82)92097-9. [DOI] [PubMed] [Google Scholar]
  10. Kuroki S., Tsutsui T., Yoshioka M., Mizue H., Kita M., Kishida T. The effect of intraventricular interferon on subacute sclerosing panencephalitis. Brain Dev. 1989;11(1):65–69. doi: 10.1016/s0387-7604(89)80012-9. [DOI] [PubMed] [Google Scholar]
  11. Ogle J. W., Toltzis P., Parker W. D., Alvarez N., McIntosh K., Levin M. J., Lauer B. A. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis. 1989 Apr;159(4):748–750. doi: 10.1093/infdis/159.4.748. [DOI] [PubMed] [Google Scholar]
  12. Panitch H. S., Gomez-Plascencia J., Norris F. H., Cantell K., Smith R. A. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology. 1986 Apr;36(4):562–566. doi: 10.1212/wnl.36.4.562. [DOI] [PubMed] [Google Scholar]
  13. Sugita T., Shiraki K., Ueda S., Iwa N., Shoji H., Ayata M., Kato S. Induction of acute myoclonic encephalopathy in hamsters by subacute sclerosing panencephalitis virus. J Infect Dis. 1984 Sep;150(3):340–347. doi: 10.1093/infdis/150.3.340. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES